Erdheim-Chester disease (ECD) is a very rare disorder in which certain white blood cells (histiocytes) build up in tissues throughout the body and cause damage. Historically, treatment options were limited. Interferon-alpha, an immune-modulating therapy, became one of the first effective treatments for ECD in the early 2000s, significantly improving survival.¹

People treated with interferon-alpha often had disease stabilisation or symptom improvement, with roughly two-thirds of individuals responding.² In recent years, the discovery of common gene mutations in ECD (especially the BRAF V600E mutation) led to new targeted therapies (BRAF and MEK inhibitors) that can shrink the disease more rapidly.³ 

This article explains what ECD is, reviews how interferon-alpha has been used to treat it (with outcomes from case reports and studies), and compares interferon with newer treatments.

What is Erdheim-Chester disease?

Erdheim-Chester disease is a rare histiocytic neoplasm – essentially a disorder in which immune cells called histiocytes multiply and infiltrate different organs. It was first described in 1930, and only a few hundred cases had been reported by 2013.⁴ ECD affects adults in middle age (around their 50s–60s). It can affect multiple parts of the body, such as the long bones of the legs, the brain and pituitary gland, the heart and blood vessels, kidneys, lungs, and skin.⁵ 

Common symptoms include bone pain (often around the knees or ankles), hormonal problems like diabetes insipidus (from pituitary involvement), and organ dysfunction depending on which areas are affected.⁵ Because it can affect many organs and mimic other diseases, ECD is often difficult to diagnose. A tissue biopsy is required for confirmation – pathologists look for characteristic foamy histiocyte cells that stain positive for certain immune markers (like CD68) and negative for others (CD1a, Langerin).⁴

Researchers have discovered that ECD is driven by mutations in the histiocyte cells. About half of people with ECD have a mutation in the BRAF gene (specifically BRAF V600E), which causes the cells to grow and survive abnormally.³ Others have mutations in related growth pathways, such as the MAPK pathway. These findings helped experts to classify ECD as a type of slow-growing blood cancer and opened the door to targeted drug treatments in the 2010s. Before these advances, doctors relied on more general therapies. Various treatments such as steroids, chemotherapy drugs, and immunosuppressants were used. However, interferon-alpha emerged as the most consistently beneficial approach in the early 21st century.

Interferon-alpha: the first effective treatment

Interferon-alpha (IFN-α) is a protein that the human body produces as part of its immune response, especially to viruses and cancers. As a drug, interferon-alpha has long been used (by injection) to treat certain malignancies and viral hepatitis. In ECD, interferon-alpha was first tried around the year 2000 after anecdotal successes in similar histiocytic diseases. A landmark report in 2005 described three people with advanced ECD who were treated with interferon-alpha and showed rapid improvements in symptoms within one month.⁶ Following this, many people with ECD worldwide received interferon, and researchers began tracking their progress.

By 2011, a multi-center analysis of 53 people confirmed that interferon-α significantly improves survival in ECD.¹ In that study, patients on interferon had much better outcomes than previously seen – five-year survival rose from around 40% (historically) to about 68% with interferon therapy.¹ This was the first time that any treatment was shown to extend survival in ECD. As a result, interferon-alpha (often given in high doses or as long-acting pegylated interferon) became the standard first-line treatment for ECD throughout the 2000s and early 2010s.⁵

Clinical experience indicated that higher doses and longer duration of interferon therapy were often needed for the best results. Low doses sometimes failed to control ECD, whereas escalating to high-dose interferon over many months yielded better responses in some cases.² Many individuals stayed on interferon treatment for one to two years (or longer) to achieve maximal disease control. The optimal duration was not clear, but anecdotally, treating for up to 2 years has led to sustained remissions in certain patients.⁹

Outcomes and findings from interferon therapy

Doctors have documented interferon-alpha’s effects in numerous case reports and series. Overall, about two-thirds of people with ECD respond in some way to interferon, though the degree of benefit varies. For example, a French study in 2012 looked at 24 people with severe multi-organ ECD treated with high-dose interferon-alpha.² Approximately 67% of these individuals showed disease improvement or stabilisation on scans and clinical exams.² In nearly half of the patients, symptoms and organ function actually improved, while in about one-fifth, the disease stopped progressing (“stable disease”).² These benefits often appeared gradually over several months of therapy. Importantly, the effect of interferon differed depending on which organs were involved – for instance, heart involvement responded in a majority of cases, whereas brain involvement was somewhat less likely to improve as well.²

Some reports highlight that interferon-induced remissions can be long-lasting. After a prolonged course of interferon (e.g., 12–24 months), a subset of individuals have been able to stop the medication and remain stable for extended periods.⁹ However, others experienced disease flare-ups if interferon was withdrawn, indicating that ongoing therapy was needed in those cases.

Side effects: Interferon-alpha can cause side effects that sometimes limit its use. Common side effects include flu-like symptoms (fever, fatigue, muscle aches), mood changes (such as depression), and lowered blood cell counts. In the French high-dose study, about 54% of patients had side effects, but in most cases these were manageable and temporary.² Only 3 out of 24 people (12.5%) had to stop interferon due to adverse effects.² Doctors also found that using pegylated interferon (a weekly injection) often made treatment more tolerable while providing similar benefits.² Despite these side effects, interferon-alpha was considered reasonably safe, and it markedly slowed the disease in many people – improving symptoms and quality of life.²

It is important to note that not everyone benefits from interferon. Roughly one-third of ECD patients do not respond adequately and continue to worsen despite this therapy.² Historically, for those non-responders, doctors tried other options – for example, chemotherapy with cladribine or targeted anti-inflammatory drugs like anakinra (an IL-1 blocker) and tocilizumab (an IL-6 blocker) – based on small case reports.¹⁰ These alternatives sometimes helped individual patients, but evidence was limited. Until recently, interferon remained the mainstay of treatment if it was tolerated.

The shift to targeted therapies

The treatment landscape for ECD changed in the 2010s with the advent of targeted therapies. The discovery that many ECD patients carry the BRAF V600E mutation led to trials of BRAF inhibitor drugs (such as vemurafenib and dabrafenib). Starting around 2015, these drugs produced dramatic improvements in most mutation-positive patients, often within weeks.³ In 2017, vemurafenib became the first drug approved by the U.S. FDA for ECD (specifically for BRAF-mutated cases).⁷ In its pivotal study, about 54% of ECD patients had a major response (partial tumour shrinkage on scans), and some achieved complete remission.⁷ This represented a much faster and deeper response than seen with interferon in many cases.

For patients without the BRAF mutation (or those who cannot take BRAF inhibitors), drugs targeting the downstream MEK protein have also been effective.³ MEK inhibitors (such as cobimetinib or trametinib) can help control ECD by blocking the same cell growth pathway. Today, targeted therapies like BRAF and MEK inhibitors are often the preferred first-line treatment, especially when critical organs are involved, because they can rapidly bring aggressive disease under control.

However, targeted therapies have some drawbacks. Patients usually need to stay on these medications continuously to maintain the disease remission – if the drug is stopped, the disease often returns within a few months.⁸ Additionally, BRAF and MEK inhibitors can cause side effects such as joint pain, skin rash, fatigue, or heart rhythm changes, which sometimes require dose adjustments.⁷ 

By comparison, interferon-alpha is generally given for a finite course and, as noted above, some individuals achieved a lasting remission after finishing a course of interferon.⁹ Thus, interferon may still be considered in certain scenarios (for example, in BRAF-negative disease or when targeted drugs are unsuitable).

Summary

Interferon-alpha therapy has played a pivotal role in the history of Erdheim-Chester disease treatment. It was the first therapy shown to improve survival in ECD¹, turning what was once a highly fatal condition into a more manageable disease. Many people treated with interferon-alpha experienced durable disease control or improvement, and it served as the standard of care for over a decade.

In the current era, newer targeted therapies (BRAF and MEK inhibitors) have further improved the outlook for ECD. These drugs can produce rapid and significant responses, and they have become front-line treatments for patients with the relevant mutations. Even so, interferon-alpha remains important: it laid the groundwork for treating this rare disease and is still used for people who cannot undergo targeted therapy or lack a targetable mutation. Thanks to interferon and modern targeted treatments, individuals with ECD today have a much better chance at long-term survival and improved quality of life.